目的 探討補(bǔ)肺活血膠囊聯(lián)合沙丁胺醇治療緩解期慢性肺心病的臨床療效。方法 選擇2018年6月—2021年6月濮陽市中醫(yī)醫(yī)院收治的86例緩解期慢性肺心病患者，按照隨機(jī)數(shù)字表法分為對(duì)照組（43例）和治療組（43例）。對(duì)照組口服硫酸沙丁胺醇片，2片/次，3次/d。治療組在對(duì)照組的基礎(chǔ)上口服補(bǔ)肺活血膠囊，4粒/次，3次/d。兩組用藥14 d觀察效果。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀改善時(shí)間，肺功能第1秒用力呼氣量（FEV1）、用力肺活量（FVC）和FEV1/FVC指標(biāo)，心功能心臟每搏量（SV）、心臟心輸出量（CO）、心臟指數(shù)（CI）指標(biāo)，血清炎性因子腫瘤壞死因子-α（TNF-α）、轉(zhuǎn)化生長(zhǎng)因子-β1（TGF-β1）、白細(xì)胞介素-8（IL-8）、血管內(nèi)皮素（ET-1）水平及不良反應(yīng)情況。結(jié)果 治療后，治療組患者總有效率（95.35%）明顯高于對(duì)照組（81.40%，P＜0.05）。治療后，治療組患者癥狀改善時(shí)間比對(duì)照組明顯縮短（P＜0.05）。治療后，兩組患者FEV1、FVC、FEV1/FVC、SV、CO、CI比治療前明顯升高，而血清炎性因子TGF-β1、ET-1、TNF-α和IL-8水平比治療前明顯降低（P＜0.05），且治療后治療組肺功能和心功能指標(biāo)明顯高于對(duì)照組（P＜0.05），血清炎性因子水平明顯低于對(duì)照組（P＜0.05）。治療后，治療組不良反應(yīng)總發(fā)生率為9.30%，明顯低于對(duì)照組（16.28%，P＜0.05）。結(jié)論 補(bǔ)肺活血膠囊聯(lián)合沙丁胺醇治療緩解期慢性肺心病效果確切，能顯著提高心肺功能，減弱機(jī)體炎性反應(yīng)，且不良反應(yīng)低。

Objective To explore the clinical study of Bufei Huoxue Capsules combined with salbutamol in treatment of chronic cor pulmonale in remission. Methods Patients (86 cases) with chronic cor pulmonale in remission in Chinese Medicine Hospital of Puyang from June 2018 to June 2021 were divided into control (43 cases) and treatment (43 cases) group by the random number table method. Patients in the control group was po administered with Salbutamol Sulfate Tablets, 2 tablets/time, three times daily. Patients in the treatment group were po administered with Bufei Huoxue Capsules on the basis of the control group, 4 pills/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, and the improvement time of symptom, the pulmonary function indexes of FEV1, FVC, and FEV1/FVC, cardiac function index of SV, CO, and CI, level of serological index TGF-β1, ET-1, TNF-α, and IL-8, and adverse reaction in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group (95.35%) was significantly higher than that of the control group (81.40%, P < 0.05). After treatment, the improvement time of symptom in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the indexes of FEV1, FVC, FEV1/FVC, SV, CO, and CI in two groups were significantly higher than those before treatment, while the levels of TGF- β 1, ET-1, TNF- α, and IL-8 were significantly lower than those before treatment (P < 0.05). After treatment, the indexes of pulmonary function and cardiac function in the treatment group were significantly higher than those in the control group (P < 0.05), and the level of serum inflammatory factors in the treatment group was significantly lower than that in the control group (P < 0.05). After treatment, the total incidence of adverse reactions in the treatment group was 9.30%, which was significantly lower than that in the control group (16.28%, P < 0.05). Conclusion Bufei Huoxue Capsules combined with salbutamol is effective in the treatment of chronic cor pulmonale in remission stage, which can significantly improve cardiopulmonary function and weaken inflammatory reaction, and the adverse reaction is low.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20190501）